C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,619,682 | -41.3% | 6,247,141 | -13.2% | 0.07% | -39.2% |
| Q2 2023 | $19,798,600 | +10.3% | 7,199,491 | +26.0% | 0.12% | +7.1% |
| Q1 2023 | $17,948,306 | -47.3% | 5,716,021 | -1.0% | 0.11% | -51.1% |
| Q4 2022 | $34,076,618 | -34.5% | 5,775,698 | -2.7% | 0.23% | -36.7% |
| Q3 2022 | $52,045,000 | +21.8% | 5,934,476 | +4.7% | 0.36% | +34.1% |
| Q2 2022 | $42,727,000 | +14.5% | 5,666,658 | +268.3% | 0.27% | +46.7% |
| Q1 2022 | $37,325,000 | -10.5% | 1,538,525 | +18.8% | 0.18% | +8.2% |
| Q4 2021 | $41,714,000 | -30.4% | 1,295,462 | -3.5% | 0.17% | -30.3% |
| Q3 2021 | $59,963,000 | +14.0% | 1,342,047 | -3.4% | 0.24% | +14.6% |
| Q2 2021 | $52,578,000 | +31.0% | 1,389,489 | +28.1% | 0.21% | +18.3% |
| Q1 2021 | $40,135,000 | – | 1,085,007 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |